Terns Pharmaceuticals, Inc.
TERN
Rang in Aktien
#3573
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Aktienkurs
$52.95
Zuletzt synchronisiert: 2026-05-15
Marktkapitalisierung
$4.77B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
529.61%
Land
US
Handel Terns Pharmaceuticals, Inc. (TERN)
Kategorie
Healthcare
P/B-Verhältnis für Terns Pharmaceuticals, Inc. (TERN)
P/B-Verhältnis zum October 2026 TTM: 4.90
Laut den neuesten Finanzberichten und dem Aktienkurs von Terns Pharmaceuticals, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 4.90. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 1.81.
P/B-Verlauf für Terns Pharmaceuticals, Inc. von 2018 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 4.90 | 285.92% |
| 2024 | 1.27 | -29.68% |
| 2023 | 1.81 | 36.73% |
| 2022 | 1.32 | 18.84% |
| 2021 | 1.11 | -83.46% |
| 2020 | 6.74 | -93.86% |
| 2019 | 109.70 | 1,697.47% |
| 2018 | 6.10 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | 27.54% |
US
|
|
| 13.2547 | 170.44% |
US
|
|
| 4.208 | -14.14% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 26.14% |
NL
|
